Compare ADMA Biologics Inc (ADMA) vs Prudential Financial Inc (PRU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Prudential Financial Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Prudential Financial Inc trades at $112.62 (market cap $40.11B). The key difference: Prudential Financial Inc is far larger — about 18.8× ADMA Biologics Inc's market cap, and Prudential Financial Inc pays a 4.85% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | PRU | |
|---|---|---|
Market Cap | $2.13B | $40.11B |
Sector | Health | Financials |
52-Week High | $20.38 | $118.72 |
52-Week Low | $7.60 | $92.00 |
Enterprise Value | $2.20B | $67.16B |
Dividend Yield | — | 4.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
PRU trades at $115.47, up 2.23% today, with a bullish technical signal and strong moving average support. The company reported a net income margin of 5.5% in 2025, with recent earnings beats in Q1 2026. Recent developments include expansion in India's life insurance market and new ETF launches by PGIM, highlighting growth initiatives.
Outlook remains positive due to solid profitability and strategic expansions, but risks include volatile cash flows and high debt levels. Analyst consensus is cautious with a hold-heavy rating, though the current price exceeds the $98.64 target, suggesting limited near-term upside amid steady operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
